Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03738618 · ClinicalTrials.gov registry record · Phase 3
Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)
A Phase 3 study, sponsored by Ferring Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 588
- Enrollment target
NCT03738618 is a Phase 3 study that has completed, run by Ferring Pharmaceuticals. The registered enrollment target is 588 participants.
The verdict
NCT03738618, a Phase 3 study, has completed, sponsored by Ferring Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 588 participants
- Enrollment target
Study Summary
This trial investigates the effects of FE 999049 compared to placebo.
Interventions
- DRUG Placebo
- DRUG Follitropin delta
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 588 participants |
| Start Date | 2018-10-29 |
| Est. Completion | 2020-12-21 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03738618
The ClinicalTrials.gov registry entry for NCT03738618 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 588 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Ferring Pharmaceuticals, which has 83 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT03738618 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03738618 about?
NCT03738618 is a clinical study titled "Recombinant FSH Investigation in the Treatment of Infertility With Assisted Reproductive Technology (ART) (RITA-2)". This trial investigates the effects of FE 999049 compared to placebo.
What is the current status of trial NCT03738618?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 588 participants. The study started on 2018-10-29. Estimated completion is 2020-12-21.
What interventions are being tested in trial NCT03738618?
The interventions under investigation include: Placebo (DRUG), Follitropin delta (DRUG).
Who is sponsoring clinical trial NCT03738618?
This trial is sponsored by Ferring Pharmaceuticals, which has 83 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.